{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibhe7w35f7ef4qilsagihe4wk2yjr32ufauvkftohxiweablskida",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mf35pqhxm6u2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreid7zezmxujxltxn55wacx5zxjrhengn4dkid5brelw4o3fszhgx7e"
    },
    "mimeType": "image/jpeg",
    "size": 414212
  },
  "path": "/news/2026-02-fda-drug-reverse-cell-exclusion.html",
  "publishedAt": "2026-02-17T12:00:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment. Fibrolamellar carcinoma primarily affects children and young adults and accounts for up to 2% of all liver cancers. It currently has no cure and has often metastasized by the time it is detected, leaving patients with a short life expectancy.",
  "title": "FDA-approved drug may reverse T-cell exclusion in fibrolamellar liver cancer"
}